23.10.2015 19:15:00
|
AbbVie Inc. -- Moody's: Viekira warnings credit negative for AbbVie
New York, October 23, 2015 -- Moody's Investors Service commented that new warnings by the US Food and Drug Administration (FDA) on AbbVie's hepatitis C drug Viekira Pak are credit negative because of lower sales potential. There is no impact on AbbVie's Baa1 ratings at this time, and the rating outlook remains negative.